Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation

Trial Profile

A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Registrational; Therapeutic Use
  • Sponsors Correvio Pharma; Merck Sharp & Dohme
  • Most Recent Events

    • 14 Aug 2018 According to a Cardiome Pharma media release, the China Food and Drug Administrations (CFDA) Center for Drug Evaluation (CDE) selected Brinavess as potentially eligible for priority review in China.Also, Brinavess was named one of 48 drugs deemed clinically urgent and targeted for expedited clearance based on existing ex-china clinical data which included positive results from this trial.
    • 07 Nov 2014 Primary endpoint has been met (conversion to sinus rhythm, assessed within 90 minutes after first exposure), according to a Cardiome Pharma media release.
    • 07 Nov 2014 Results published in a Cardiome Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top